Effects of combination therapy of beta-interferon Ia and prednisone on serum immunologic markers in patients with multiple sclerosis

Multiple Sclerosis

Volumn 9, Issue 1, 2003, Pages 28-31

  Salama, Hassan H ^a,b   Kolar, Oldrich J ^d   Zang, Ying C Q ^a,c   Zhang, Jingwu ^a,c  

^a Multiple Sclerosis Res Laboratory   (United States)

^b MANSOURA UNIVERSITY   (Egypt)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d Indiana Ctr for Multiple Sclerosis   (United States)

Author keywords

Beta interferon; Cytokines; Multiple sclerosis; T cells

Indexed keywords

BETA1A INTERFERON; BIOLOGICAL MARKER; CYTOKINE; FAS ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2 RECEPTOR; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BINDING AFFINITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG BINDING; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG INHIBITION; DRUG POTENTIATION; FEMALE; FLU LIKE SYNDROME; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOREGULATION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PROTEIN BLOOD LEVEL; PROTEIN SYNTHESIS INHIBITION; RECEPTOR UPREGULATION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

ADJUVANTS, IMMUNOLOGIC; ADULT; ANTI-INFLAMMATORY AGENTS; ANTIGENS, CD95; BIOLOGICAL MARKERS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; INTERFERON-BETA; INTERLEUKIN-10; INTERLEUKIN-12; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PREDNISONE; RECEPTORS, INTERLEUKIN-2; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0037330509     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1191/1352458503ms865oa     Document Type: Article

References (9)

1. Martin R, McFarland H.F. Immunological aspects of experimental mental allergic encephalomyelitis and multiple sclerosis. Crit Rev Clin Lab Sci 1995; 32: 121-82.
2. Navikas V, Link H. Cytokines and the pathogenesis of multiple sclerosis. J Neurosci Res 1996; 45: 322-33.
3. Olsson T. Critical influences of the cytokine orchestration on the outcome of myelin antigen-specific T-cell autoimmunity in experimental autoimmune encephalomyelitis and multiple sclerosis. Immunol Rev 1995; 144: 245-68.
4. Hartung HP et al. Circulating adhesion molecules and tumor necrosis factor receptor in multiple sclerosis: Correlation with magnetic resonance imaging. Ann Neurol 1995; 38: 186-93.
5. Zang YC et al. Immunoregulation and blocking antibodies induced by interferon beta treatment in MS. Neurology 2000; 55: 397-404.
6. Rep MH et al. Interferon (IFN)-beta treatment enhances CD95 and interleukin 10 expression but reduces interferon-gamma producing T cells in MS patients. J Neuroimmunol 1999; 96: 92-100.
7. Rudick RA et al. In vivo effects of interferon beta-1a on immunosuppressive cytokines in multiple sclerosis. Neurology 1998; 50: 1294-1300.
8. Rott O et al. Interleukin-10 prevents experimental allergic encephalomyelitis in rats. Eur J Immunol 1994; 24: 1434-40.
9. Zipp F et al. Increased serum levels of soluble CD95 (APO-1/Fas) in relapsing-remitting multiple sclerosis. Ann Neurol 1998; 43: 116-20.